Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 7;7(1):e135.
doi: 10.1038/ctg.2015.63.

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Giulia Roda  1 , Bindia Jharap  2 , Narula Neeraj  1 , Jean-Frederic Colombel  1
Affiliations

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Giulia Roda et al. Clin Transl Gastroenterol. .

Abstract

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response-PNR) or lose response during the treatment (secondary loss of response-LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Management of patients with LOR. CRP, C reactive protein; LOR, loss of response.
See this image and copyright information in PMC

References

    1. 1Sherman M, Tsynman DN, Kim A et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014; 15: 174–179. - PubMed
    1. 2Sprakes MB, Ford AC, Warren L et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012; 6: 143–153. - PubMed
    1. 3Hanauer SB, Feagan BG, Lichtenstein GR et al. ACCENT I Study group. Maintanance Infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 59: 1541–1549. - PubMed
    1. 4Sands B, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876–885. - PubMed
    1. 5Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644–659. - PubMed